Table 2.
Real-World Performance of Sofosbuvir and Simeprevir in HIV/HCV-Coinfected Patients by Pretreatment Fibrosis Stage and HCV Genotypea
| Cohort | SVR12 | ||||||
|---|---|---|---|---|---|---|---|
| CROI 2015 Abstract (Authors) | No. | Treatment Experienced | Metavir Fibrosis Stage F3 or F4 | Genotype 1 | Genotype 1a | Genotype 1b | Comments |
| 644 (Marks et al) | 15 | 100% | 67% (F4 only) | 93% (14/15) | -- | -- | All prior HCV PI treatment failures without detectable resistance |
| 645 (Gilmore et al) | 37 | 49% | 78% | 81% (30/37) | 74% (17/23) | 93% (13/14) | ITT analysis; 4/7 treatment failures were lost to follow-up (all 4 attained SVR4) |
| 647 (Del Bello et al) | 34 | 53% | 56% | 90% (26/29) | -- | -- | As treated |
| 649 (Grant et al) | 33 | -- | 53% (F4 only) | 95% (18/19) | 92% (11/12) | 100% (7/7) | As treated; 1 patient treated for 24 weeks |
Abbreviations: CROI, Conference on Retroviruses and Opportunistic Infections; HCV, hepatitis C virus; ITT, intention to treat; PI, protease inhibitor; SVR4(12), sustained virologic response 4 (12) weeks after cessation of therapy.
a
A ll patients treated for 12 weeks unless noted. Ribavirin used in some patients; unable to assess impact of ribavirin in these datasets.